Les Laboratoires Servier SAS – Product Pipeline Review

Global Markets Direct’s, ‘Les Laboratoires Servier SAS – Product Pipeline Review – 2016’, provides an overview of the Les Laboratoires Servier SAS’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Les Laboratoires Servier SAS, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the pipeline therapeutic landscape of Les Laboratoires Servier SAS

The report provides overview of Les Laboratoires Servier SAS including its business description, key facts, and locations and subsidiaries

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report assesses Les Laboratoires Servier SAS’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report features Les Laboratoires Servier SAS’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

Evaluate Les Laboratoires Servier SAS’s strategic position with total access to detailed information on its product pipeline

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Les Laboratoires Servier SAS

Identify potential new clients or partners in the target demographic

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Les Laboratoires Servier SAS’s pipeline depth and focus of pipeline therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Les Laboratoires Servier SAS Snapshot 6

Les Laboratoires Servier SAS Overview 6

Key Information 6

Key Facts 6

Les Laboratoires Servier SAS - Research and Development Overview 7

Key Therapeutic Areas 7

Les Laboratoires Servier SAS - Pipeline Review 10

Pipeline Products by Stage of Development 10

Pipeline Products - Monotherapy 11

Pipeline Products - Combination Treatment Modalities 12

Pipeline Products - Partnered Products 13

Partnered Products/Combination Treatment Modalities 14

Les Laboratoires Servier SAS - Pipeline Products Glance 15

Les Laboratoires Servier SAS - Late Stage Pipeline Products 15

Pre-Registration Products/Combination Treatment Modalities 15

Phase III Products/Combination Treatment Modalities 16

Les Laboratoires Servier SAS - Clinical Stage Pipeline Products 17

Phase II Products/Combination Treatment Modalities 17

Phase I Products/Combination Treatment Modalities 18

Les Laboratoires Servier SAS - Early Stage Pipeline Products 19

Preclinical Products/Combination Treatment Modalities 19

Discovery Products/Combination Treatment Modalities 20

Les Laboratoires Servier SAS - Drug Profiles 21

(amlodipine besylate + perindopril) 21

Product Description 21

Mechanism of Action 21

R&D Progress 21

ivabradine hydrochloride 23

Product Description 23

Mechanism of Action 23

R&D Progress 23

(amlodipine besylate + indapamide + perindopril) 24

Product Description 24

Mechanism of Action 24

R&D Progress 24

(atorvastatin calcium + perindopril) 25

Product Description 25

Mechanism of Action 25

R&D Progress 25

(indapamide + perindopril) 26

Product Description 26

Mechanism of Action 26

R&D Progress 26

lucitanib 27

Product Description 27

Mechanism of Action 27

R&D Progress 27

S-38093 30

Product Description 30

Mechanism of Action 30

R&D Progress 30

S-38844 31

Product Description 31

Mechanism of Action 31

R&D Progress 31

S-47445 32

Product Description 32

Mechanism of Action 32

R&D Progress 32

S-49076 33

Product Description 33

Mechanism of Action 33

R&D Progress 33

NMSP-153 34

Product Description 34

Mechanism of Action 34

R&D Progress 34

S-055746 35

Product Description 35

Mechanism of Action 35

R&D Progress 35

Small Molecule to Inhibit Mcl-1 for Cancer 36

Product Description 36

Mechanism of Action 36

R&D Progress 36

Drugs to Inhibit Insulin-Regulated AminoPeptidase for Alzheimer’s Disease 37

Product Description 37

Mechanism of Action 37

R&D Progress 37

Monoclonal Antibodies for Cancer 38

Product Description 38

Mechanism of Action 38

R&D Progress 38

Drugs for Triple Negative Breast Cancer 39

Product Description 39

Mechanism of Action 39

R&D Progress 39

Small Molecules for Central Nervous System Disorders 40

Product Description 40

Mechanism of Action 40

R&D Progress 40

Les Laboratoires Servier SAS - Pipeline Analysis 41

Les Laboratoires Servier SAS - Pipeline Products by Target 41

Les Laboratoires Servier SAS - Pipeline Products by Route of Administration 43

Les Laboratoires Servier SAS - Pipeline Products by Molecule Type 44

Les Laboratoires Servier SAS - Pipeline Products by Mechanism of Action 45

Les Laboratoires Servier SAS - Recent Pipeline Updates 47

Les Laboratoires Servier SAS - Dormant Projects 52

Les Laboratoires Servier SAS - Discontinued Pipeline Products 53

Discontinued Pipeline Product Profiles 53

agomelatine 53

terutroban 53

Les Laboratoires Servier SAS - Company Statement 54

Les Laboratoires Servier SAS - Locations And Subsidiaries 55

Head Office 55

Other Locations & Subsidiaries 55

Appendix 59

Methodology 59

Coverage 59

Secondary Research 59

Primary Research 59

Expert Panel Validation 59

Contact Us 59

Disclaimer 60

List of Tables

List of Tables

Les Laboratoires Servier SAS, Key Information 6

Les Laboratoires Servier SAS, Key Facts 6

Les Laboratoires Servier SAS – Pipeline by Indication, 2016 8

Les Laboratoires Servier SAS – Pipeline by Stage of Development, 2016 10

Les Laboratoires Servier SAS – Monotherapy Products in Pipeline, 2016 11

Les Laboratoires Servier SAS – Combination Treatment Modalities in Pipeline, 2016 12

Les Laboratoires Servier SAS – Partnered Products in Pipeline, 2016 13

Les Laboratoires Servier SAS – Partnered Products/ Combination Treatment Modalities, 2016 14

Les Laboratoires Servier SAS – Pre-Registration, 2016 15

Les Laboratoires Servier SAS – Phase III, 2016 16

Les Laboratoires Servier SAS – Phase II, 2016 17

Les Laboratoires Servier SAS – Phase I, 2016 18

Les Laboratoires Servier SAS – Preclinical, 2016 19

Les Laboratoires Servier SAS – Discovery, 2016 20

Les Laboratoires Servier SAS – Pipeline by Target, 2016 41

Les Laboratoires Servier SAS – Pipeline by Route of Administration, 2016 43

Les Laboratoires Servier SAS – Pipeline by Molecule Type, 2016 44

Les Laboratoires Servier SAS – Pipeline Products by Mechanism of Action, 2016 45

Les Laboratoires Servier SAS – Recent Pipeline Updates, 2016 47

Les Laboratoires Servier SAS – Dormant Developmental Projects,2016 52

Les Laboratoires Servier SAS – Discontinued Pipeline Products, 2016 53

Les Laboratoires Servier SAS, Other Locations 55

Les Laboratoires Servier SAS, Subsidiaries 55

List of Figures

List of Figures

Les Laboratoires Servier SAS – Pipeline by Top 10 Indication, 2016 8

Les Laboratoires Servier SAS – Pipeline by Stage of Development, 2016 10

Les Laboratoires Servier SAS – Monotherapy Products in Pipeline, 2016 11

Les Laboratoires Servier SAS – Combination Treatment Modalities in Pipeline, 2016 12

Les Laboratoires Servier SAS – Partnered Products in Pipeline, 2016 13

Les Laboratoires Servier SAS – Pipeline by Top 10 Target, 2016 41

Les Laboratoires Servier SAS – Pipeline by Route of Administration, 2016 43

Les Laboratoires Servier SAS – Pipeline by Molecule Type, 2016 44

Les Laboratoires Servier SAS – Pipeline Products by Top 10 Mechanism of Action, 2016 45

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports